Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Rating) – Research analysts at William Blair raised their FY2022 EPS estimates for shares of Pyxis Oncology in a research note issued to investors on Tuesday, November 1st. William Blair analyst R. Prasad now anticipates that the company will post earnings per share of ($3.47) for the year, up from their prior estimate of ($3.48). The consensus estimate for Pyxis Oncology's current full-year earnings is ($3.41) per share. William Blair also issued estimates for Pyxis Oncology's Q4 2022 earnings at ($0.86) EPS, Q1 2023 earnings at ($0.92) EPS, Q2 2023 earnings at ($0.98) EPS, Q3 2023 earnings at ($0.86) EPS, Q4 2023 earnings at ($0.91) EPS and FY2023 earnings at ($3.65) EPS.

Pyxis Oncology Price Performance

Pyxis Oncology stock opened at $1.53 on Friday. Pyxis Oncology has a 12 month low of $1.49 and a 12 month high of $13.75. The stock has a fifty day simple moving average of $2.04 and a two-hundred day simple moving average of $2.39.

Hedge Funds Weigh In On Pyxis Oncology

A number of hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. purchased a new stake in shares of Pyxis Oncology during the 2nd quarter valued at about $31,000. Acuta Capital Partners LLC raised its stake in Pyxis Oncology by 222.6% during the 2nd quarter. Acuta Capital Partners LLC now owns 645,149 shares of the company's stock valued at $1,535,000 after buying an additional 445,149 shares during the last quarter. Laurion Capital Management LP lifted its holdings in shares of Pyxis Oncology by 159.9% during the 2nd quarter. Laurion Capital Management LP now owns 3,170,803 shares of the company's stock valued at $7,547,000 after buying an additional 1,950,971 shares during the period. Millennium Management LLC bought a new stake in shares of Pyxis Oncology in the second quarter worth $340,000. Finally, Renaissance Technologies LLC purchased a new stake in Pyxis Oncology during the second quarter valued at $179,000. Hedge funds and other institutional investors own 71.59% of the company's stock.

Pyxis Oncology Company Profile

(Get Rating)

Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.

Read More

• Get a free copy of the StockNews.com research report on Pyxis Oncology (PYXS)
• MarketBeat: Week in Review 10/31-11/4
• Is Hershey's a Sweet Stock to Buy After a Post-Earnings Dip?
• Datadog Doesn't Belong In The Doghouse
• Nikola Shares Fall Even As EV Maker Beats Q3 Expectations
• Mixed Results Actually Bring More Optimism than Risk for AMD

Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.